Redmile Group Reports 9.9% Stake in ADC Therapeutics Following Internal Reorganization

On April 24, 2026, Redmile Group, LLC and Jeremy C. Green filed a Schedule 13G/A regarding their holdings in ADC Therapeutics SA (ADCT). The filing reports a beneficial ownership of 12,717,487 shares, representing 9.9% of the company. This figure includes 12,604,885 common shares and 112,602 shares issuable upon the exercise of pre-funded warrants, subject to a 9.99% beneficial ownership blocker. The amendment primarily reflects an internal reorganization effective April 20, 2026. RedCo II Master Fund, L.P. contributed its entire position pro rata to its wholly-owned subsidiaries, including RedCo II Offshore SPV LLC, for no consideration. Consequently, RedCo II Master Fund, L.P. ceased to be a beneficial owner and filed to exit, while RedCo II Offshore SPV LLC became a beneficial owner of 7,780,431 shares (6.1%). This internal transfer resulted in a slight increase in total shares held by Redmile Group from 12,692,841 to 12,717,487, though the overall ownership percentage remained stable at 9.9%.